License Revenue - Related Party was Ovid Therapeutics’s largest product and service line in fiscal 2021, bringing in $196.00M of $208.38M (94%).
| Product and Service | FY 2020 | FY 2021 |
|---|---|---|
| License Revenue - Related Party | — | $196.00M |
| License & Other Revenue | — | $12.38M |
| License | $12.62M | — |
| Total | $12.62M | $208.38M |
Ovid Therapeutics brought in $208.38M from its two product and service lines in fiscal 2021, the year ended December 31, 2021. Ovid Therapeutics regrouped these lines after fiscal 2020, so the total does not compare directly with that year's $12.62M. License Revenue - Related Party was the largest at $196.00M (94.1%), ahead of License & Other Revenue at $12.38M (5.9%).
Ovid Therapeutics began breaking out License Revenue - Related Party in fiscal 2021 and License & Other Revenue in fiscal 2021. Ovid Therapeutics stopped reporting License as a separate line after fiscal 2020, when it brought in $12.62M.
Ovid Therapeutics (OVID) reports its revenue by product and service. In fiscal 2021, License Revenue - Related Party was its largest product and service line, bringing in $196.00M (94.1% of the total), followed by License & Other Revenue at $12.38M (5.9%).
License Revenue - Related Party was Ovid Therapeutics' largest product and service line in fiscal 2021, bringing in $196.00M, or 94.1% of the $208.38M total across its two product and service lines.
Every figure comes from Ovid Therapeutics' annual financial filings, as reported. Each line keeps the name Ovid Therapeutics gives it, and years follow its fiscal calendar.
Ovid Therapeutics' revenue by product and service goes back to fiscal 2020, with figures through fiscal 2021. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.